Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Japan to Require Out-of-Pocket Cost for COVID Drugs from October
September 19, 2023
- New Health Minister Vows to Put Public Needs First in 2024 Drug Pricing Reform
September 15, 2023
- Japan to Basically Drop Japanese PI Requirement before Global Clinical Trials
September 14, 2023
- Chuikyo Mixed on Expanding Range of CEA Price Adjustments for Pricey Meds
September 14, 2023
- Bimzelx, Pivlaz Escape Price Cuts after Cost-Effectiveness Assessments
September 14, 2023
- Keizo Takemi Tapped as New Health Minister in Cabinet Reshuffle
September 14, 2023
- MHLW Must Take Big Step on Drug Lags, Losses in FY2024 Reform: Official
September 13, 2023
- University Hospital Reform Report Finds Inadequate Review of High-Price Drug Use
September 13, 2023
- Respond to Wage Hikes for Medical Workers in FY2024 Reform: Ex-Minister
September 13, 2023
- Japan’s Envisaged IP Tax Relief Likely to Cover Drug Sales, METI Eyes FY2024 Rollout
September 13, 2023
- Moderna’s Omicron XBB.1.5 Vaccine Snags Japan Approval
September 12, 2023
- New MHLW Drug Review Chief Vows to Make Japan Attractive Place for Clinical Trials, Watching Debate on Japanese PI
September 12, 2023
- New Working Group to Propose Effective Collection and Sharing of Drug Supply Info by March-End
September 12, 2023
- Japan to End Free COVID Vaccine Program in March, Weighs NIP Inclusion
September 11, 2023
- Japan Panel OKs Use of Pfizer’s XBB.1.5 Jab for Fall Vaccination Campaign
September 11, 2023
- PMDA Reviewing Safety Risks for G-CSF Agents, Yervoy and More
September 11, 2023
- MHLW Panel OKs Changes to Guidelines for Using NDB, Anonymized Medical Data
September 11, 2023
- Japan Mulling Once-a-Year COVID Booster for Elderly in FY2024
September 8, 2023
- MHLW Moving Toward Allowing Use of Cannabis-Derived Drugs: LDP Session
September 8, 2023
- LDP Lawmakers Deplore Reported GMP Issues at Sawai
September 8, 2023
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…